Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2008 1
2009 1
2012 1
2013 1
2014 1
2015 1
2016 1
2017 2
2018 2
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium. Kenna JG, et al. Among authors: pak ya. Clin Pharmacol Ther. 2018 Nov;104(5):916-932. doi: 10.1002/cpt.1222. Clin Pharmacol Ther. 2018. PMID: 30137645 Free PMC article. Review.
Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.
Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM. Posada MM, et al. Among authors: pak ya. Clin Transl Sci. 2017 Nov;10(6):509-519. doi: 10.1111/cts.12486. Epub 2017 Jul 27. Clin Transl Sci. 2017. PMID: 28749581 Free PMC article. Clinical Trial.
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H. Bentz J, et al. Among authors: pak ya. Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25. Drug Metab Dispos. 2013. PMID: 23620485 Free PMC article.
Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
Varma MV, Eriksson AH, Sawada G, Pak YA, Perkins EJ, Zimmerman CL. Varma MV, et al. Among authors: pak ya. Drug Metab Dispos. 2009 Jan;37(1):211-20. doi: 10.1124/dmd.108.022012. Epub 2008 Oct 6. Drug Metab Dispos. 2009. PMID: 18838508
11 results